U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07121998) titled 'Study of Acquired Resistance to Alkylator Chemotherapy in Endocrine Neoplasms' on June 17.
Brief Summary: It has been showed that alkylating chemotherapy, particularly the widely used agent temozolomide, may cause high tumor mutational burden (TMB) in certain tumors by causing inactivating mutations in the DNA mismatch repair (MMR) system. This can cause therapy resistance and tumor progression but may also predict response for immunotherapy. Hypermutation is very uncommon in neuroendocrine tumors. However, small studies indicate that around 30% of pancreatic tumors develop high TMB after alkylating chemotherapy. The aim of this stu...